Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00865410 · ClinicalTrials.gov registry record · Phase 1

A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets Under Fasting Conditions

A Phase 1 study of Healthy, sponsored by Actavis.

Completed
Registry status
Phase 1
Development phase
26
Enrollment target
1
Study location

NCT00865410 is a Phase 1 study of Healthy that has completed, run by Actavis. The registered enrollment target is 26 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00865410, a Phase 1 study of Healthy, has completed, sponsored by Actavis.

COMPLETED
Registry status
Phase 1
Development phase
26 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to compare the rate and extent of absorption of Bupropion HCl extended-release tablet (test) to that of Wellbutrin SR extended-release tablet (reference) after a single, one-tablet (150 mg) dose in fasted subjects.

Conditions Studied

Interventions

  • DRUG Abrika Bupropion 150 mg Extended-Released Tablet
  • DRUG Wellbutrin SR® 150 mg Extended-Release Tablet, single dose

Study Locations (1)

Florida

  • SFBC Ft. Myers, Inc. - Fort Myers

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2004-08
Est. Completion 2004-09
Phase Phase 1

Sponsor

Actavis

79 total trials

What the Registry Record Tells You About NCT00865410

The ClinicalTrials.gov registry entry for NCT00865410 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The listed sponsor is Actavis, which has 79 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Abrika Bupropion 150 mg Extended-Released Tablet is the first listed.

NCT00865410 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT00865410 about?

NCT00865410 is a clinical study titled "A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets Under Fasting Conditions". The purpose of this study is to compare the rate and extent of absorption of Bupropion HCl extended-release tablet (test) to that of Wellbutrin SR extended-release tablet (reference) after a single, one-tablet (150 mg) dose in fasted subjects.

What is the current status of trial NCT00865410?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2004-08. Estimated completion is 2004-09.

What conditions does trial NCT00865410 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT00865410?

The interventions under investigation include: Abrika Bupropion 150 mg Extended-Released Tablet (DRUG), Wellbutrin SR® 150 mg Extended-Release Tablet, single dose (DRUG).

Who is sponsoring clinical trial NCT00865410?

This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00865410 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.